Lilly wins breakthrough designation for breast cancer drug
The FDA has granted Lilly's abemaciclib breakthrough therapy designation for the treatment of advanced breast cancer. The designation comes on the back of data from Lilly's phase I JPBA trial which studied the efficacy and safety of abemaciclib in women with advanced or metastic breast cancer who had received a median of seven prior treatments. Richard Gaynor, senior VP of product development and medical affairs for Lilly, said:
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
